<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041977</url>
  </required_header>
  <id_info>
    <org_study_id>DERM-303</org_study_id>
    <nct_id>NCT00041977</nct_id>
  </id_info>
  <brief_title>Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CollaGenex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CollaGenex Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg&#xD;
      Tablets, taken twice daily is effective in reducing the red and white heads and overall&#xD;
      redness associated with rosacea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>150</enrollment>
  <condition>Acne Rosacea</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline hyclate 20 mg twice daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Healthy, post-pubescent male and females &gt; age 18, with rosacea, 10 to 30, [papules&#xD;
             and pustules] and &lt; 2 nodules.&#xD;
&#xD;
          -  Presence of moderate to severe erythema.&#xD;
&#xD;
          -  Presence of telangiectasia.&#xD;
&#xD;
          -  Female patients must utilize one of the following methods of birth control throughout&#xD;
             the study: IUD, diaphragm, a condom plus the use of a spermicidal gel or foam, oral&#xD;
             contraceptives (provided patient has been utilizing this method for at least 4 months&#xD;
             prior to baseline and has not changed the brand within this period). Patients may also&#xD;
             participate if they are surgically sterilized, in a monogamous relationship with a&#xD;
             sterile partner, or sign an agreement that they will abstain from sexual intercourse&#xD;
             during the course of a study.&#xD;
&#xD;
          -  Patients must sign an informed consent form.&#xD;
&#xD;
          -  Negative pregnancy test and non-lactating.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The initiation of a hormonal method of contraception within 4 months of baseline; or&#xD;
             discontinuation during the course of study; or change in the actual product within 4&#xD;
             months of baseline or during the study.&#xD;
&#xD;
          -  The use of topical acne treatments within 2 weeks of baseline.&#xD;
&#xD;
          -  The use of systemic antibiotics within 4 weeks of baseline.&#xD;
&#xD;
          -  The use of an investigational drug with 90 days of baseline.&#xD;
&#xD;
          -  Pregnant women or women of child-bearing potential who are not using an adequate form&#xD;
             of birth control as described in Item 4 of the Inclusion Criteria.&#xD;
&#xD;
          -  Nursing women.&#xD;
&#xD;
          -  Patients with a known hypersensitivity to tetracyclines.&#xD;
&#xD;
          -  Patients on clinically significant, concomitant drug therapy (See section below).&#xD;
&#xD;
          -  The use of any acne treatment during the course of the study.&#xD;
&#xD;
          -  The use of topical steroids 6 weeks prior to baseline and during the study.&#xD;
&#xD;
          -  The use of systemic corticosteroids 6 weeks prior to baseline and during the study.&#xD;
&#xD;
          -  The use of vasodilators 6 weeks prior to baseline or during the study.&#xD;
&#xD;
          -  The use of Î±-adrenergic receptor-blocking agents 6 weeks prior to baseline and during&#xD;
             the study.&#xD;
&#xD;
        Prohibited Medications:&#xD;
&#xD;
          -  Chronic use (&gt; 14 days) of sulfa drugs, erythromycin, cephalosporins, and quinolones.&#xD;
&#xD;
          -  The use of tetracycline antibiotics is prohibited.&#xD;
&#xD;
          -  Use of any acne treatment during the course of the study, including spironolactone.&#xD;
&#xD;
          -  Chronic use (&gt; 14 days) of NSAIDs. Chronic use of aspirin at sub-analgesic doses (&lt;&#xD;
             325 mg q.d.) may be used by those patient requiring platelet aggregation inhibitor.&#xD;
&#xD;
          -  Penicillin antibiotics should NOT be used during the course of this trial since the&#xD;
             bacteriostatic action of doxycycline may interfere with the bactericidal action of&#xD;
             penicillins.&#xD;
&#xD;
          -  Antacids and vitamins containing aluminum, calcium, or magnesium may impair drug&#xD;
             absorption and should be taken at least 1.5 hours before or 3.0 hours after taking&#xD;
             study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beer and Houck/Florida Dermatology Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Pariser, MD</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2003</verification_date>
  <study_first_submitted>July 19, 2002</study_first_submitted>
  <study_first_submitted_qc>July 22, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

